Directori de persones
Jose Manuel Valdivielso Revilla

Jose Manuel Valdivielso Revilla

Grau: Doctor

973 702 952
valdivielso(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/B-5673-2009

Publicacions

  • Valls J; Cambray S; Pérez-Guallar C; Bozic M; Bermúdez-López M; Fernández E; Betriu À; Rodríguez I; Valdivielso JM

    Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort.

    Frontiers in Genetics 10 118-118. .

    [doi:10.3389/fgene.2019.00118]

  • Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M

    SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

    NEPHROLOGY DIALYSIS TRANSPLANTATION 34 208-230. .

    [doi:10.1093/ndt/gfy407]

  • Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C

    Lipid management in patients with chronic kidney disease (vol 14, pg 727, 2018)

    NATURE REVIEWS NEPHROLOGY 15 121-121. .

    [doi:10.1038/s41581-018-0099-y]

  • Chang AR; Grams ME; Ballew SH; Bilo H; Correa A; Evans M; Gutierrez OM; Hosseinpanah F; Iseki K; Kenealy T; Klein B; Kronenberg F; Lee BJ; Li Y; Miura K; Navaneethan SD; Roderick PJ; Valdivielso JM; Visseren FLJ; Zhang L; Gansevoort RT; Hallan SI; Levey AS; Matsushita K; Shalev V; Woodward M; CKD Prognosis Consortium (CKD-PC)

    Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium

    BMJ-BRITISH MEDICAL JOURNAL 364 k5301-. .

    [doi:10.1136/bmj.k5301]

  • Valdivielso JM; Jacobs-Cachá C; Soler MJ

    Sex hormones and their influence on chronic kidney disease.

    CURR OPIN NEPHROL HY 28 1-9. .

    [doi:10.1097/MNH.0000000000000463]

  • Rayego-Mateos S; Rodrigues-Diez R; Morgado-Pascual JL; Valentijn F; Valdivielso JM; Goldschmeding R; Ruiz-Ortega M

    Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage

    Mediators of Inflammation 2018 8739473-8739473. .

    [doi:10.1155/2018/8739473]

  • Morgado-Pascual JL; Marchant V; Rodrigues-Diez R; Dolade N; Suarez-Alvarez B; Kerr B; Valdivielso JM; Ruiz-Ortega M; Rayego-Mateos S

    Epigenetic Modification Mechanisms Involved in Inflammation and Fibrosis in Renal Pathology

    Mediators of Inflammation 2018 2931049-2931049. .

    [doi:10.1155/2018/2931049]

  • Borràs, Mercè; Cambray, Serafí; Crespo-Masip, Maria; Pérez-Fontán, Miguel; Bozic, Milica; Bermudez-López, Marcelino; Fernández, Elvira; Betriu, Àngels; Valdivielso, José M.

    Peritoneal Dialysis Is an Independent Factor Associated to Lower lntima Media Thickness in Dialysis Patients Free From Previous Cardiovascular Disease

    Frontiers in physiology 9 1743-1743. .

    [doi:10.3389/fphys.2018.01743]

  • Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C

    Lipid management in patients with chronic kidney disease

    NATURE REVIEWS NEPHROLOGY 14 727-749. .

    [doi:10.1038/s41581-018-0072-9]

  • Montserrat-Capdevila J; Seminario MA; Godoy P; Marsal JR; Ortega M; Pujol J; Castañ MT; Alsedà M; Betriu À; Lecube A; Portero M; Purroy F; Valdivielso JM; Barbé F

    Prevalence of chronic obstructive pulmonary disease (COPD) not diagnosed in a population with cardiovascular risk factors

    MEDICINA CLINICA 151 383-389. .

    [doi:10.1016/j.medcli.2017.12.018]

  • Arcidiacono MV; Rimondi E; Maietti E; Melloni E; Tisato V; Gallo S; Valdivielso JM; Fernández E; Betriu À; Voltan R; Zauli G; Volpato S; Secchiero P

    Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.

    PLOS ONE 13 e0203716-. .

    [doi:10.1371/journal.pone.0203716]

  • Palanca, A; Castelblanco, E; Perpinan, H; Betriu, A; Soldevila, B; Valdivielso, JM; Bermudez, M; Duran, X; Fernandez, E; Puig-Domingo, M; Groop, PH; Alonso, N; Mauricio, D

    Prevalence and progression of subclinical atherosclerosis in patients with chronic kidney disease and diabetes

    Atherosclerosis 276 50-57. .

    [doi:10.1016/j.atherosclerosis.2018.07.018]

Projectes

  • Papel de la vía PI3K/AKT/mTOR en la regulación de las alteraciones del metabolismo mineral en la enfermedad renal crónica. Implicaciones en la regulación de la síntesis de FGF23.
  • Red de investigación Renal: REDINREN
  • Papel de la expresión renal de alfa sinucleina en la enfermedad renal crónica. Implicaciones en la patogénesis de la fibrosis renal
  • MOVILIDAD DE PROFESIONALES SANITARIOS E INVESTIGADORES DEL SNS (M-BAE)
  • IDENTIFYING PREDICTORS OF CARDIOVASCULAR EVENTS IN CHRONIC KIDNEY DISEASE. A COHORTS SUBSTUDY WITHIN THE NEFRONA STUDY
  • ESTANCIAS DE PROFESORES E INVESTIGADORES SENIORES EN CENTROS EXTRANJEROS, PROGRAMA SALVADOR DE MADARIAGA 2012
  • PAPEL DE LA FALTA DE VITAMINA D EN LA PROGRESION DE LA PLACA ATEROSCLEROTICA. IMPLICACIONES ENF LA ARTERIOPATIA UREMICA
  • PAPEL DEL RECEPTOR DE VITAMINA D EN LA PROGRESION DEL CICLO CELULAR Y LA SENESCENCIA DE LAS CELULAS DE MUSCULO LISO VASCULAR. IMPLICACIONES EN LA FORMACION DE PLACA DE ATEROMA.
  • REGULACION DE LA SINTESIS VASCULAR DE CALCITRIOL EN CONDICIONES NORMALES EN LA UREMIA. EFECTOS DEL TRATAMIENTO CON VITAMINA D Y ANALOGOS
  • ROLE OF VDR ON VASCULAR SMOOTH CELLS BIOLOGY
  • PAPEL DE LOS RECEPTORES RENALES DE NMDA EN EL FRACASO RENAL EXPERIMENTAL. RELACION CON EL NO.
  • Papel de los receptores renales de NMDA en el fracaso renal experimental. Relación con el NO